March isn’t quite over as we write this, and neither is the madness—which won’t stop us from posting the biggest deals of the month. As of Friday, March 27, $34.4 billion has been committed to finance about 105 transactions. Of course, $21 billion of that comes from the AbbVie (NYSE: ABBV) acquisition of Pharmacyclics (NASDAQ: […]
Already in 2015, we’ve recorded 11 billion-dollar-plus deals, for a total of $64.4 billion. Thanks to the $21 billion AbbVie (NYSE: ABBV) bid for Pharmacyclics (NASDAQ: PCYC), the biotechnology sector accounted for $27.5 billion of those big deals. Pharmaceuticals, with four billion-plus transactions, still ranks first, with combined spending of $30.45 billion.